Literature DB >> 6609963

Human lung macrophages enhance and inhibit lymphocyte proliferation.

M C Liu, D Proud, R P Schleimer, M Plaut.   

Abstract

To evaluate the effector functions of human lung macrophages, cell preparations containing 70 to 95% macrophages were obtained from surgically resected lungs of cancer patients and were co-cultured with allogeneic or autologous peripheral blood mononuclear cells (PBMC) and Con A. In contrast to previous reports of either marked stimulatory or inhibitory effects of human lung macrophages on lymphocyte function, the present results demonstrate that the proliferative response was a complex function of both the numbers of PBMC and macrophages. In the presence of low numbers of PBMC, small numbers of macrophages enhanced proliferation, whereas larger numbers inhibited proliferation; in the presence of larger numbers of PBMC, macrophages only inhibited. Inhibition was not mediated by cyclo-oxygenase products of arachidonic acid metabolism, because indomethacin did not reverse it. The enhancing effect of macrophages was greater when tested with PBMC depleted of monocytes. Lung macrophages were 10-fold more potent in mediating enhancement than corresponding numbers of peripheral blood monocytes. Both the enhancing and the inhibitory activities could be reproduced by lung macrophage lysates or supernatants derived from macrophages cultured in serum-free medium. Macrophages cultured at high density yielded inhibitory supernatants, which on dilution resulted in enhancing activity. The enhancing activity appeared in supernatants maximally after 24 hr, and its appearance was not inhibited by culturing macrophages in the presence by culturing macrophages in the presence of cycloheximide. Sephacryl S-200 chromatography of such supernatants yielded two peaks of enhancing activity, with apparent m.w. of 160,000 and 40,000, which we call lung macrophage-derived lymphocyte-activating factors (LM-LAF). Fractions with LM-LAF activity contained no IL 1 activity (assessed by augmentation of mitogen-induced proliferation of mouse thymocytes), but IL 1 activity was present in a peak of m.w. of 15,000. The 15,000 m.w. fraction did not enhance the proliferation of human PBMC. These results demonstrate that human lung macrophages are potent modulators of lectin-mediated proliferation of human PBMC. The effects are mediated in part by the release of soluble, pre-formed factors that appear to be distinct from previously described monokines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609963

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor.

Authors:  Sharonjit K Gill; Yiwen Yao; Linda J Kay; Martin A Bewley; Helen M Marriott; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

2.  Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease.

Authors:  D A Campbell; L W Poulter; R M Du Bois
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

3.  Suppression of autologous peripheral blood mononuclear cell proliferation by alveolar macrophages from young infants.

Authors:  H J Bunn; C R A Hewitt; J Grigg
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Four monoclonal antibodies, AMH-1, -2, -3, and -4, give varied reactivities with monocytes, alveolar macrophages, and epithelioid-cell granulomas.

Authors:  J Akiyama; K Chida; A Sato; A Yamashita
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

5.  Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.

Authors:  D Valeyre; P Soler; C Clerici; J Pré; J P Battesti; R Georges; A J Hance
Journal:  Thorax       Date:  1988-07       Impact factor: 9.139

6.  Suppressor cell activity of human alveolar macrophages in interstitial lung diseases.

Authors:  E M Fireman; S Ben Efraim; J Greif; S Kivity; M R Topilsky
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

7.  Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony-stimulating factor.

Authors:  N Bilyk; P G Holt
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.